While ibrutinib was primarily responsible for targeting BTK, it also inhibited several other kinases, including (Interleukin-2-Inducible T-Cell Kinase) ITK, (Tyrosine Kinase Expressed in Hepatocellular Carcinoma) TEC, and (Tyrosine Kinase Non-Receptor 1) TXK [32]. Here, ITK is linked to hepatocellular carcinoma.